Lower dose radiation for slow-growing lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a slow-growing type of B-cell lymphoma, such as follicular, marginal zone, or follicle center lymphoma.
- Your lymphoma is at any stage (early or advanced).
- You are starting treatment for the first time, your lymphoma is not responding to treatment, or it has come back after treatment.
- You are able to get out of bed and care for yourself most of the day (ECOG score 0-3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to take detailed pictures of slow-growing lymphomas, likely before or after your regular treatment scan. It may help your doctor see exactly where the lymphoma is in your body.
This trial tests whether a lower dose of radiation, guided by PET scans, is safe and effective for people with early-stage but unfavorable Hodgkin lymphoma. It aims to reduce side effects while keeping the treatment strong.
This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.
This trial tests whether a shorter, gentler course of chemotherapy (bendamustine plus rituximab) works just as well for slow-growing lymphomas like follicular lymphoma. The 'MRD-guided' part means the doctors will use a blood test to see if the cancer is gone, and they may stop treatment earlier if it is.
This study tests a new way to treat slow-growing non-Hodgkin lymphoma that has come back or not responded to other treatments. It combines special immune cells with a targeted therapy to try to destroy cancer cells.
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Hear when a new Indolent B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.